# A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma

> **NCT03221348** · PHASE1 · UNKNOWN · sponsor: **Cho Pharma Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** CHO-H01

## Key facts

- **NCT ID:** NCT03221348
- **Lead sponsor:** Cho Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03
- **Primary completion:** 2019-10
- **Final completion:** 2019-11
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2018-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221348, "A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03221348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*